Cisplatin Eligibility Issues and Alternative Regimens in Locoregionally Advanced Head and Neck Cancer: Recommendations for Clinical Practice

Well-designed randomized trials provide the highest level of scientific evidence to guide clinical decision making. In chemoradiotherapy of locally advanced squamous cell carcinoma of the head and neck (SCCHN), data support the use of three cycles of 100 mg/m(2) cisplatin given every 3 weeks concurr...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Front Oncol
Main Authors: Szturz, Petr, Cristina, Valerie, Herrera Gómez, Ruth Gabriela, Bourhis, Jean, Simon, Christian, Vermorken, Jan B.
Formato: Artigo
Idioma:Inglês
Publicado: Frontiers Media S.A. 2019
Assuntos:
Oncology
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6579895/
https://ncbi.nlm.nih.gov/pubmed/31245288
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.00464
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares